Latest news and major announcements from our companies.

April 2024

Richelieu Hardware Completes Acquisitions of Olympic Forest, Rapid Start and Allegheny Plywood

Mars 2024

FDA Approves Idorsia’s TRYVIO, the First and Only Endothelin Receptor Antagonist for the Treatment of High Blood Pressure

February 2024

Gear Energy Ltd. Announces Completion of the Strategic Repositioning Process and Intention to Commence Normal Course Issuer Bid

January 2024

Knight Therapeutics Inc. Celebrates its First Decade of Success

December 2023

Generation Bio Announces Strategic Reorganization to Extend Cash Runway for Development of ctLNP and iqDNA Platforms

November 2023

Statement from Daily Journal Corporation Regarding the Passing of Charles T. Munger

October 2023

Peyto Announces Closing of Repsol Acquisition

September 2023

Generation Bio Announces Breakthrough in its Non-Viral Genetic Medicine Platform with Novel “Immune-Quiet” DNA

June 2023

Petrus Resources Announces Credit Facility Increase and Approval For Normal Course Issuer Bid

March 2023

Generation Bio and Moderna Announce Strategic Collaboration to Develop Non-Viral Genetic Medicines

January 2023

Richelieu Hardware Increased Sales by 25.2% in 2022 with Accelerated Growth in the United States of 42.2%

November 2022

Groupe Guillin Acquires Irish Company Celtic Sales Ltd

October 2022

Peyto Announces Leadership Update

July 2022

Tessenderlo Group and Picanol Group Announce Intention to Simplify Group Structure and Combine Activities

May 2022

Petrus Resources Announces Closing of Oversubscribed Rights Offering

February 2022

All Preferred Shares and Preference Units of Inc. Converted

January 2022

FDA Approves Idorsia’s QUVIVIQ for the Treatment of Adults with Insomnia

October 2021

Idorsia Announces the Results of MODIFY, a Phase 3 Study of Lucerastat in Fabry Disease

July 2021

Richelieu Hardware Records Strong Growth and Pursues Successful Acquisition Strategy

June 2021

Groupe Guillin Acquires Gault & Fremont

April 2021

Knight Therapeutics to Acquire Regional Rights to Exelon

March 2021

FDA Approves Idorsia’s PONVORY to Treat Adults with Relapsing Forms of Multiple Sclerosis

January 2021

Constellation Software Inc. Completes Spin-Out of Inc.